Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-04-21
DOI
10.1038/s41598-017-00791-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
- (2016) Boyang Zhao et al. CELL
- Stochasticity in the Genotype-Phenotype Map: Implications for the Robustness and Persistence of Bet-Hedging
- (2016) Daniel Nichol et al. GENETICS
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stochasticity in the Genotype-Phenotype Map: Implications for the Robustness and Persistence of Bet-Hedging
- (2016) Daniel Nichol et al. GENETICS
- Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
- (2015) Irina Kareva et al. CANCER LETTERS
- Rational Design of Antibiotic Treatment Plans: A Treatment Strategy for Managing Evolution and Reversing Resistance
- (2015) Portia M. Mira et al. PLoS One
- Collateral sensitivity of antibiotic-resistant microbes
- (2015) Csaba Pál et al. TRENDS IN MICROBIOLOGY
- Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance
- (2015) Daniel Nichol et al. PLoS Computational Biology
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Use of Collateral Sensitivity Networks to Design Drug Cycling Protocols That Avoid Resistance Development
- (2013) L. Imamovic et al. Science Translational Medicine
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
- (2012) J. Tanizaki et al. CLINICAL CANCER RESEARCH
- Collateral sensitivity as a strategy against cancer multidrug resistance
- (2012) Kristen M. Pluchino et al. DRUG RESISTANCE UPDATES
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
- (2011) A. Becker et al. EUROPEAN JOURNAL OF CANCER
- Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer
- (2011) Jin Ho Paik et al. LUNG CANCER
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive Therapy
- (2009) R. A. Gatenby et al. CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Is resistance useless? Multidrug resistance and collateral sensitivity
- (2009) Matthew D. Hall et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies
- (2009) Jasmine Foo et al. PLoS Computational Biology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started